Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ankle replacement

This article was originally published in The Gray Sheet

Executive Summary

Intermediate outcomes for total ankle replacement are similar to those for ankle fusion, but well-designed comparative studies are needed to confirm this conclusion, according to Steven Haddad, M.D., Northwestern University. Haddad is the author of a meta-analysis of ankle surgery studies in the September Journal of Bone and Joint Surgery, the first such systematic analysis comparing the two procedures. The analysis includes 49 primary studies, 10 of which evaluated total ankle replacement in a total of 852 patients and 39 of which evaluated ankle arthrodesis in a total of 1,262 patients. Of the patients treated with second generation total ankle replacement devices, 82% had excellent or good results compared to 72% of patients treated with traditional ankle fusion. Direct comparative meta-analysis of total ankle replacement and fusion was not possible because there have been no head-to-head trials. The analysis was sponsored by Johnson & Johnson/DePuy, maker of the 510(k)-cleared Agility Total Ankle System

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts